AffiliationUniversity of Arizona, Department of Chemistry and Biochemistry
central nervous system
blood brain barrier penetration
MetadataShow full item record
PublisherBENTHAM SCIENCE PUBL LTD
CitationCyclic Opioid Peptides. 2016, 23 (13):1288-303 Curr. Med. Chem.
JournalCurrent medicinal chemistry
RightsCopyright © 2016, Eureka Science Ltd.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractFor decades the opioid receptors have been an attractive therapeutic target for the treatment of pain. Since the first discovery of enkephalin, approximately a dozen endogenous opioid peptides have been known to produce opioid activity and analgesia, but their therapeutics have been limited mainly due to low blood brain barrier penetration and poor resistance to proteolytic degradation. One versatile approach to overcome these drawbacks is the cyclization of linear peptides to cyclic peptides with constrained topographical structure. Compared to their linear parents, cyclic analogs exhibit better metabolic stability, lower offtarget toxicity, and improved bioavailability. Extensive structure-activity relationship studies have uncovered promising compounds for the treatment of pain as well as further elucidate structural elements required for selective opioid receptor activity. The benefits that come with employing cyclization can be further enhanced through the generation of polycyclic derivatives. Opioid ligands generally have a short peptide chain and thus the realm of polycyclic peptides has yet to be explored. In this review, a brief history of designing ligands for the opioid receptors, including classic linear and cyclic ligands, is discussed along with recent approaches and successes of cyclic peptide ligands for the receptors. Various scaffolds and approaches to improve bioavailability are elaborated and concluded with a discourse towards polycyclic peptides.
Note12 month embargo. Published 1 April 2016.
VersionFinal accepted manuscript
- Cyclization in opioid peptides.
- Authors: Piekielna J, Perlikowska R, Gach K, Janecka A
- Issue date: 2013 Jun
- Development of opioid peptide analogs for pain relief.
- Authors: Janecka A, Perlikowska R, Gach K, Wyrebska A, Fichna J
- Issue date: 2010
- Cyclic mu-opioid receptor ligands containing multiple N-methylated amino acid residues.
- Authors: Adamska-Bartłomiejczyk A, Janecka A, Szabó MR, Cerlesi MC, Calo G, Kluczyk A, Tömböly C, Borics A
- Issue date: 2017 Apr 15
- New trends in the development of opioid peptide analogues as advanced remedies for pain relief.
- Authors: Gentilucci L
- Issue date: 2004
- Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor.
- Authors: Meunier JC
- Issue date: 1997 Dec 4